يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Alonso-Gordoa, Teresa"', وقت الاستعلام: 1.63s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study

    المؤلفون: Grünwald, Viktor, Powles, Thomas, Kopyltsov, Evgeny, Kozlov, Vadim, Alonso-Gordoa, Teresa, Eto, Masatoshi, Hutson, Thomas, Motzer, Robert, Winquist, Eric, Maroto, Pablo, Keam, Bhumsuk, Procopio, Giuseppe, Wong, Shirley, Melichar, Bohuslav, Rolland, Frederic, Oya, Mototsugu, Rodriguez-Lopez, Karla, Saito, Kenichi, McKenzie, Jodi, Porta, Camillo

    المساهمون: Grünwald, Viktor, Powles, Thoma, Kopyltsov, Evgeny, Kozlov, Vadim, Alonso-Gordoa, Teresa, Eto, Masatoshi, Hutson, Thoma, Motzer, Robert, Winquist, Eric, Maroto, Pablo, Keam, Bhumsuk, Procopio, Giuseppe, Wong, Shirley, Melichar, Bohuslav, Rolland, Frederic, Oya, Mototsugu, Rodriguez-Lopez, Karla, Saito, Kenichi, Mckenzie, Jodi, Porta, Camillo

    مصطلحات موضوعية: Depth of response, Lenvatinib, Pembrolizumab, Renal cell carcinoma, Sunitinib

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36720658; info:eu-repo/semantics/altIdentifier/wos/WOS:001051202100001; journal:EUROPEAN UROLOGY ONCOLOGY; https://hdl.handle.net/11586/434871Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85166362238

    الإتاحة: https://doi.org/10.1016/j.euo.2023.01.010Test
    https://hdl.handle.net/11586/434871Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

    المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

    المساهمون: Gennigens, Christine

    المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

    مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

    العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

    الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test

    View record in ORBi

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance.

    المؤلفون: Araujo-Castro, Marta, Pascual-Corrales, Eider, Molina-Cerrillo, Javier, Alonso-Gordoa, Teresa, Subramanian, Chitra

    المصدر: Biomedicines; Mar2021, Vol. 9 Issue 3, p304, 1p

    مصطلحات موضوعية: IMMUNE checkpoint inhibitors, IMMUNOTHERAPY, PROGRESSION-free survival, ADRENAL tumors, CARCINOMA

    النص الكامل

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

    المؤلفون: Choueiri, Toni K1 (AUTHOR) toni_choueiri@dfci.harvard.edu, Eto, Masatoshi2 (AUTHOR), Motzer, Robert3 (AUTHOR), De Giorgi, Ugo4 (AUTHOR), Buchler, Tomas5 (AUTHOR), Basappa, Naveen S6 (AUTHOR), Méndez-Vidal, María José7 (AUTHOR), Tjulandin, Sergei8 (AUTHOR), Hoon Park, Se9 (AUTHOR), Melichar, Bohuslav10 (AUTHOR), Hutson, Thomas11 (AUTHOR), Alemany, Carlos12 (AUTHOR), McGregor, Bradley1 (AUTHOR), Powles, Thomas13,14 (AUTHOR), Grünwald, Viktor15 (AUTHOR), Alekseev, Boris16 (AUTHOR), Rha, Sun Young17 (AUTHOR), Kopyltsov, Evgeny18 (AUTHOR), Kapoor, Anil19 (AUTHOR), Alonso Gordoa, Teresa20 (AUTHOR)

    المصدر: Lancet Oncology. Mar2023, Vol. 24 Issue 3, p228-238. 11p.

    مصطلحات موضوعية: *RENAL cell carcinoma, *SUNITINIB, *ENDOTHELIAL growth factors, *PEMBROLIZUMAB, *KARNOFSKY Performance Status

    الشركة/الكيان: MEMORIAL Sloan-Kettering Cancer Center , MERCK & Co. Inc. 001317064 MRK


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث